<DOC>
	<DOCNO>NCT00052715</DOCNO>
	<brief_summary>RATIONALE : Biological therapy poly-ICLC use different way stimulate immune system stop tumor cell grow . Radiation therapy use high-energy x-rays damage tumor cell . Combining biological therapy radiation therapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine poly-ICLC radiation therapy treat patient newly diagnose glioblastoma multiforme .</brief_summary>
	<brief_title>Biological Therapy Radiation Therapy Treating Patients With Newly Diagnosed Glioblastoma Multiforme</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy poly ICLC radiotherapy , term total survival date diagnosis , patient newly diagnose glioblastoma multiforme . - Determine safety toxicity profile regimen patient . - Determine 12-month survival rate patient treat regimen . - Assess progression-free survival 6 month median progression-free survival date diagnosis patient treat regimen . - Assess response patient treat regimen . - Assess change neurological status patient treat regimen . OUTLINE : This multicenter study . Within 1-4 week surgery , patient receive poly ICLC intramuscularly 3 time weekly ( day 1 , 3 , 5 ) . Treatment continue absence disease progression unacceptable toxicity . One week initiation poly ICLC , patient undergo external beam radiotherapy daily 5 day week 6 week . Patients follow monthly 1 year every 3 month thereafter . PROJECTED ACCRUAL : A total 60 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Poly ICLC</mesh_term>
	<mesh_term>Poly I-C</mesh_term>
	<mesh_term>Carboxymethylcellulose Sodium</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm intracranial glioblastoma multiforme ( GBM ) gliosarcoma biopsy resection within past 28 day PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 60100 % Life expectancy More 8 week Hematopoietic WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10 g/dL ( transfusion allow ) Hepatic Bilirubin less 2 time upper limit normal ( ULN ) SGOT le 2 time ULN Renal Creatinine le 1.5 mg/dL Other No significant medical illness control adequately appropriate therapy would compromise tolerability study therapy No cancer ( except nonmelanoma skin cancer carcinoma situ cervix ) unless complete remission therapy disease least 3 year No active infection No disease would obscure toxicity dangerously alter drug metabolism No serious concurrent medical illness Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior polifeprosan 20 carmustine implant ( Gliadel wafer ) No concurrent chemotherapy Endocrine therapy Concurrent corticosteroid treat symptom prevent complication allow Radiotherapy No prior radiotherapy brain No concurrent stereotactic radiosurgery No concurrent brachytherapy Surgery See Disease Characteristics Other No prior cytotoxic noncytotoxic drug therapy GBM No prior experimental drug therapy GBM No concurrent cytotoxic noncytotoxic drug therapy GBM Concurrent analgesic , antiepileptic , drug treat symptom prevent complication allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>